Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura J Esserman

Showing results (1-10 of 308) with videos related to

Pageof 31
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2020
Personalization of Treatment is the Way Forward in Care and TrialsLaura J Esserman
Clinical Advances in Hematology & Oncology : H&O|September 8, 2021
The use of neoadjuvant therapy to further personalize breast cancer treatmentLaura J Esserman
Cancer Journal (Sudbury, Mass.)|June 22, 2002
New approaches to the imaging, diagnosis, and biopsy of breast lesionsLaura J Esserman
NPJ Breast Cancer|September 26, 2017
The WISDOM Study: breaking the deadlock in the breast cancer screening debateLaura J Esserman,
Oncology (Williston Park, N.Y.)|September 6, 2014
Breast cancer recurrence is dictated by high-risk biology, not choice of surgeryLaura J Esserman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2014
Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change?Laura J Esserman, Angela DeMichele
Nature Medicine|April 25, 2024
Reproductive rights in the United States: acquiescence is not a strategyLaura J Esserman, Douglas Yee
BMJ (Clinical Research Ed.)|January 25, 2019
Should we rename low risk cancers?Laura J Esserman, Murali Varma
JAMA|December 22, 2011
Accelerating identification and regulatory approval of investigational cancer drugsLaura J Esserman, Janet Woodcock
Nature Reviews. Clinical Oncology|November 6, 2013
Screening: biology dictates the fate of young women with breast cancerMartin Eklund, Laura J Esserman
Pageof 31

Showing results (1-10 of 308) with videos related to

Sort By:
Pageof 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2020
Personalization of Treatment is the Way Forward in Care and TrialsLaura J Esserman
Clinical Advances in Hematology & Oncology : H&O|September 8, 2021
The use of neoadjuvant therapy to further personalize breast cancer treatmentLaura J Esserman
Cancer Journal (Sudbury, Mass.)|June 22, 2002
New approaches to the imaging, diagnosis, and biopsy of breast lesionsLaura J Esserman
NPJ Breast Cancer|September 26, 2017
The WISDOM Study: breaking the deadlock in the breast cancer screening debateLaura J Esserman,
Oncology (Williston Park, N.Y.)|September 6, 2014
Breast cancer recurrence is dictated by high-risk biology, not choice of surgeryLaura J Esserman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2014
Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change?Laura J Esserman, Angela DeMichele
Nature Medicine|April 25, 2024
Reproductive rights in the United States: acquiescence is not a strategyLaura J Esserman, Douglas Yee
BMJ (Clinical Research Ed.)|January 25, 2019
Should we rename low risk cancers?Laura J Esserman, Murali Varma
JAMA|December 22, 2011
Accelerating identification and regulatory approval of investigational cancer drugsLaura J Esserman, Janet Woodcock
Nature Reviews. Clinical Oncology|November 6, 2013
Screening: biology dictates the fate of young women with breast cancerMartin Eklund, Laura J Esserman
Pageof 31